Sandvine Appoints Chief Ethics & Compliance Officer and Board Advisor as Part of Strengthened Commitment to Internet Freedom and Digital Rights
15.1.2025 18:41:00 CET | Business Wire | Press release
Carol Tate will serve as CCO following her tenure as Chief Compliance Officer at IntelFormer President & CEO of Human Rights First, Michael Breen, appointed as Advisor to the Board of Directors
Today, Sandvine (the “Company”), a market-leading provider of Over-the-Top (OTT) Application Classification and Quality of Experience (QoE) solutions, announced the appointments of Carol Tate as Chief Ethics & Compliance Officer, effective February 3, and Michael Breen as Advisor to the Board of Directors, effective January 1. Working closely with teams across the Company and in collaboration with its Board of Directors, Tate will spearhead compliance and due diligence initiatives to help facilitate Sandvine’s transition into a technology solution leader for democracies. Working directly with the Company’s Board of Directors, Breen is advising on human rights matters, including its engagement with non-governmental organizations to inform the Company’s human rights due diligence.
With decades of legal, risk, and compliance experience in the public and private sectors, Tate brings extensive experience embedding ethics and compliance into technological deployment and innovation on a global scale. She most recently served as Vice President and Chief Compliance Officer at Intel Corporation (NASDAQ: INTC) (“Intel”), where she led the organization’s global ethics and compliance function, which included driving initiatives to promote the company’s values and ethical culture, encourage open reporting, and reinforce Intel’s commitment to product responsibility in connection with Intel’s technology.
Prior to Intel, Tate held senior leadership roles within the ethics and compliance functions at McCarthy Holdings, Inc., Flextronics International Ltd., and Motorola. She also served as a senior attorney with the U.S. Securities and Exchange Commission’s Enforcement Division.
“As we operate in an increasingly complex digital environment, Sandvine’s focus on driving technological innovation while promoting internet freedom and digital rights could not be more critical,” said Tate. “I am excited to join a team and organization focused on providing high-quality products and premier customer service while facing these challenges head-on through close and productive partnerships with all stakeholders.”
Breen, an executive leader, strategist, policy expert and former military officer, has diverse experience leading complex organizations at the intersection of technology, global security, human rights, politics, and markets. He previously served as President & CEO of Human Rights First, a US-based organization confronting global human rights abuse, authoritarianism, and extremism through technology innovation and deployment, crisis response, policy development and advocacy, research, and legal services. Prior to leading Human Rights First, Breen acted as President & CEO of the Center for National Policy and the Truman National Security Project, served in the Obama administration’s Office of White House Counsel, and co-founded the International Refugee Assistance Project. He began his career as a decorated US Army officer, leading soldiers in combat in Iraq and Afghanistan.
“At a critical inflection point, Sandvine worked diligently to rechart its course, commit to being a positive and material contributor to the protection of human rights around the world, and double down on its mission to help people work, learn, entertain, and communicate. That resilience speaks to the Company’s potential to build itself into a values-driven technology solutions market leader,” said Breen. “I look forward to working closely with the Sandvine Board of Directors and the Company’s executive leadership team to help Sandvine navigate the challenges of today’s digital landscape.”
“Sandvine’s appointments of Carol and Michael are a direct reflection of the Company’s strengthened commitment to internet freedom and both digital and human rights, and we are honored to welcome them aboard,” added Carney Hawks, Chairman of the Board of Sandvine. “Carol’s extensive and successful track record collaborating with government and regulatory stakeholders, customers, trade groups, NGOs, and colleagues to deliver technological excellence governed by the highest ethical standards, combined with Michael’s exceptional background leading organizations dedicated to mitigating the world’s most complex issues across technology, human rights, global security and political dimensions, will be immensely valuable to Sandvine in this new chapter.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115186859/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom